Anticoagulation in Cancer Related Stroke "OASIS-CANCER"


Phase N/A Results N/A

Trial Description

Purpose: Cancer associated intravascular coagulopathy is the primary mechanism of cancer-related stroke, particularly in those without conventional stroke etiologies. Randomized clinical trials have investigated efficacy of vitamin K-dependent oral anticoagulant (warfarin), low-molecular-weight heparin (LMWH) and non-vitamin K-dependent oral anticoagulant (NOAC) for the prevention of systematic venous thromboembolism. However, relatively little is known about the biological changes underlying intravascular coagulopathy and mechanisms of anticoagulation therapy in patients with cancer-related stroke. The aim of this study is to evaluate to determine the biological markers for intravascular coagulopathy causing stroke and for monitoring the effects of anticoagulation therapy, in patients with active cancer and stroke.



  • Anticoagulation treatment. Drug
    Intervention Desc: Details of anticoagulation treatment information will be gathered including low molecular-weight heparin (enoxaparin 1 mg/kg) vs. NOAC (rivaroxaban 15 or 20 mg), vs. warfarin (target INR2.0-3.0) or no use of anticoagulation per physicians' decision and patients' conditions.

Trial Design

  • Observation: Cohort
  • Perspective: Prospective
  • Sampling: Non-Probability Sample

Trial Population

Acute ischemic stroke patients with active cancer


Type Measure Time Frame Safety Issue
Primary Recurrent stroke or systemic embolism up to 6 months No
Secondary 90-days modified Rankin Scale score examined at 90 days after stroke symptom onset in each patients No
Secondary Effect of anticoagulation treatment up to 14 days No
Secondary Symptomatic hemorrhagic transformation up to 6 months Yes